EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study

Fangshu Guan, Yi Zhang, Xing Guo, Fei Cheng, Enfan Zhang, Jingsong He, Zhen Cai, Yi Zhao

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06507-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Fangshu Guan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bone Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the efficacy and safety of brentuximab vedotin (BV) combined with a CHP-like regimen (cyclophosphamide, doxorubicin, and prednisone) as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL). We retrospectively analyzed the clinical data of patients with PTCL who received BV in combination with a CHP-like regimen as first-line therapy between January 2021 and October 2023. Fifty patients were included in this study, with a median age of 57 years (rang, 22-86 years). The median number of BV cycles administered was six (range, 2-8 cycles). After a median follow-up of 35.2 months (95% confidence interval [CI], 30.9-39.5), the overall response rate (ORR) was 80%, with 44% of the patients achieving a complete response (CR). In patients with the ALK-positive anaplastic large cell lymphoma (ALCL) subtype, the CR rate was 70.6%. The median progression-free survival (PFS) was 39.7 months (95% CI, 14.7-NA), whereas the median overall survival (OS) was not reached (the 1-year OS rate, 90%). Multivariate analysis indicated that bone marrow infiltration at diagnosis was the only factor that was significantly associated with poor OS. Neutropenia (81.3%) was the most common adverse event, and peripheral neuropathy was observed in 16.7% of patients. This real-world study suggests that BV combined with a CHP-like regimen is an effective and safe first-line treatment for patients with newly diagnosed PTCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brentuximab VedotinAntineoplastic Combined Chemotherapy ProtocolsLymphoma, T-Cell, PeripheralHumansMiddle AgedAdultMaleFemaleAgedRetrospective StudiesDoxorubicinCyclophosphamideAged, 80 and overPrednisoneYoung AdultTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

Brentuximab vedotinCHP-likeFirst-linePeripheral T-cell lymphoma

Substanzen

Brentuximab VedotinDoxorubicinCyclophosphamidePrednisone

Autor:innen und Institutionen

  • Bone Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Pathology department, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Bone Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. zhaoyi999@zju.edu.cn.

Zitieren

APA

Guan, F., Zhang, Y., Guo, X., Cheng, F., Zhang, E., He, J., Cai, Z., & Zhao, Y. (2025). Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study. Annals of Hematology. https://doi.org/10.1007/s00277-025-06507-7

Vancouver

Guan F, Zhang Y, Guo X, Cheng F, Zhang E, He J, et al. Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study. Annals of Hematology. 2025. doi:10.1007/s00277-025-06507-7

BibTeX
@article{Guan2025,
  author = {Guan, Fangshu and Zhang, Yi and Guo, Xing and Cheng, Fei and Zhang, Enfan and He, Jingsong and Cai, Zhen and Zhao, Yi},
  title = {Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06507-7}
}
Kostenlos starten →